Elanco Animal Health (NYSE:ELAN) Hits New 1-Year Low – Should You Sell?

Elanco Animal Health Incorporated (NYSE:ELAN)’s share price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $9.75 and last traded at $9.77, with a volume of 4155953 shares. The stock had previously closed at $10.77.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Barclays lowered their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Morgan Stanley dropped their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. Piper Sandler decreased their price target on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Stifel Nicolaus lowered their price objective on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Finally, UBS Group cut their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Hold” and a consensus price target of $15.17.

Elanco Animal Health Stock Performance

The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a market cap of $4.55 billion, a PE ratio of 22.91, a PEG ratio of 2.50 and a beta of 1.44. The stock has a 50 day simple moving average of $11.04 and a two-hundred day simple moving average of $12.30.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the company earned $0.08 EPS. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. Equities analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the business’s stock in a transaction on Tuesday, March 11th. The stock was bought at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the transaction, the director now owns 111,459 shares in the company, valued at $1,136,881.80. This represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.57% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Versant Capital Management Inc boosted its holdings in Elanco Animal Health by 65.9% in the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock valued at $46,000 after purchasing an additional 1,740 shares in the last quarter. Probity Advisors Inc. purchased a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $160,000. Jefferies Financial Group Inc. purchased a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $980,000. Forum Financial Management LP grew its holdings in Elanco Animal Health by 22.7% during the fourth quarter. Forum Financial Management LP now owns 16,068 shares of the company’s stock worth $195,000 after acquiring an additional 2,977 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new position in Elanco Animal Health in the fourth quarter worth $2,122,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.